PIM was identified as a STAT5 inhibitor by a high throughput screen based on STAT transcriptional activity and it decreased the survival of CML cells resistant tyrosine kinase inhibitors [96]. The gene discussed is STAT5A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.